TRAM1: A Potential Cancer Therapeutic and Biomarker (G23471)

Target Name: TRAM1

NCBI ID: G23471

TRAM1

TRAM1: A Potential Cancer Therapeutic and Biomarker

TRAM1, short for Trastuzumab (T), is a drug target and biomarker that is involved in various diseases, including cancer. Its name comes from the TRAM family of proteins, which are a type of transmembrane protein that is involved in intracellular signaling. TRAM1 is a monoclonal antibody that is designed to selectively bind to TRAM, a protein that is expressed in various cell types, including cancer cells.

The TRAM1 drug target is involved in various signaling pathways, including the TGF-β pathway, which is involved in cell growth, differentiation, and survival. The TGF-β pathway is a well-established cancer-promoting pathway that is involved in the development of various types of cancer, including breast, lung, and colorectal cancers.

TRAM1 is currently being investigated as a potential drug target for various types of cancer, including breast, lung, and colorectal cancers. Studies have shown that TRAM1 has the potential to be an effective therapeutic agent for these diseases, potentially by inhibiting the activity of TRAM, which would result in the inhibition of the TGF-β pathway.

In addition to its potential use as a cancer therapeutic, TRAM1 has also been shown to have potential as a biomarker for various types of cancer. Its ability to selectively bind to TRAM has been shown to be associated with the development and progression of various types of cancer. For example, studies have shown that TRAM1 levels are elevated in various types of cancer, including breast, lung, and colorectal cancers.

The high level of TRAM1 expression in cancer cells may also be an indication that the cancer cells are resistant to traditional cancer treatments. This suggests that TRAM1 may be an effective target for cancer cells that are resistant to traditional therapies.

TRAM1 has also been shown to have potential as a biomarker for TRAM-mediated signaling pathways. TRAM is a protein that is involved in various signaling pathways, including the TGF-β pathway. The TGF-β pathway is involved in the development and maintenance of tissues, including organs, tissues, and organs.

Studies have shown that TRAM is involved in the regulation of cellular processes that are critical for tissue growth, differentiation, and survival. In addition, TRAM is also involved in the regulation of cellular signaling pathways, including the TGF-β pathway. This suggests that TRAM may be involved in the regulation of various signaling pathways that are important for cancer development and progression.

In conclusion, TRAM1 is a drug target and biomarker that is involved in various diseases, including cancer. Its ability to selectively bind to TRAM and its involvement in the TGF-β pathway make it an attractive candidate for cancer therapeutic agents. Further research is needed to fully understand the potential of TRAM1 as a cancer therapeutic and biomarker.

Protein Name: Translocation Associated Membrane Protein 1

Functions: Involved in the translocation of nascent protein chains into or through the endoplasmic reticulum (ER) membrane by facilitating the proper chain positioning at the SEC61 channel (PubMed:1315422, PubMed:8616892, PubMed:9506517, PubMed:12475939, PubMed:32013668). Regulates the exposure of nascent secretory protein chain to the cytosol during translocation into the ER (PubMed:9506517). May affect the phospholipid bilayer in the vicinity of the lateral gate of the SEC61 channel, thereby facilitating ER protein transport (PubMed:32013668). Intimately associates with transmembrane (TM) domain of nascent membrane proteins during the entire integration process into the ER membrane (PubMed:8616892). Associates with the second TM domain of G-protein-coupled receptor opsin/OPSD nascent chain in the ER membrane, which may facilitate its integration into the membrane (PubMed:12475939). Under conditions of ER stress, participates in the disposal of misfolded ER membrane proteins during the unfolded protein response (UPR), an integrated stress response (ISR) pathway, by selectively retrotranslocating misfolded ER-membrane proteins from the ER into the cytosol where they are ubiquitinated and degraded by the proteasome (PubMed:20430023)

The "TRAM1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRAM1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets